gb2064
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 15, 2020 (NCT04679870)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Lysyl oxidase homolog 2INHIBITOR
LOXL2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04679870 | Phase 2 | Dec 15, 2020 | Galecto Biotech, OPIS s.r.l, University of Texas at Houston |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Galecto Biotech | For profit | 1 | 1 | 1 | 2020 |
| OPIS s.r.l | For profit | 1 | 0 | 1 | 2020 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1